Isavuconazole ndinavir sulfate CC1ON=C(C=1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@H](C([O-])=O)N2C1=O)C1=CC=CC=C1Cl

CC1ON=C(C=1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@H](C([O-])=O)N2C1=O)C1=CC=CC=C1Cl

MKC-3946 is an IRE1α endoribonuclease domain inhibitor that blocks XBP1 mRNA splicing and triggers modest growth inhibition in MM cells

competitive tight-binding HDAC inhibitor

followed by a surge of apoptosis

is a dopamine D2 receptor agonist used for prolactinoma treatment

Isavuconazole ndinavir sulfate CC1ON=C(C=1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@H](C([O-])=O)N2C1=O)C1=CC=CC=C1ClIsavuconazole, also knownc as BAL4815 and RO 0094815, is a triazole antifungal drug. Its prodrug, isavuconazonium sulfate (BAL8557), was granted approval by the U. S. Food and Drug Administration (FDA) on March 6, 2015 for the treatment of invasive candidiasis. Isavuconazole works by inhibiting lanosterol 14 alpha demethylase, the enzyme responsible for converting lanosterol to ergosterol by demethylation. The resulting depletion of ergosterol and